Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors

Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors

US Patent 12285431 · Granted Apr 29, 2025

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Morphic forms of trilaciclib and methods of manufacture thereof2025
Morphic forms of trilaciclib and methods of manufacture thereof2025
G1T38 superior dosage regimes2025
Substituted 1′,2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2025
Morphic forms of trilaciclib and methods of manufacture thereof2024
Transient protection of normal cells during chemotherapy2023
Transient protection of normal cells during chemotherapy2023
Transient protection of normal cells during chemotherapy2023
HSPC-sparing treatments for RB-positive abnormal cellular proliferation2023
HSPC-sparing treatments for RB-positive abnormal cellular proliferation2023
HSPC-sparing treatments for RB-positive abnormal cellular proliferation2023
Substituted 1′,2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2023